Sustained virological response with telaprevir in 1078 patients with advanced hepatitis C

The international telaprevir access program

Massimo Colombo, Simone Strasser, Christophe Moreno, Paulo Abrao Ferreira, Petr Urbanek, Inmaculada Fernández, Djamal Abdurakmonov, Adrian Streinu-Cercel, Anke Verheyen, Wafae Iraqi, Ralph DeMasi, Andrew Hill, Isabelle Lonjon-Domanec, Heiner Wedemeyer

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Background & Aims: There is little information regarding the extent to which difficult to cure patients with advanced liver fibrosis, due to hepatitis C virus genotype-1 (HCV-1) can successfully and safely be treated with triple therapy with telaprevir (TVR), pegylated interferon alpha (P) and ribavirin (R). In the TVR early access program HEP3002 we aimed to explore treatment safety and efficacy, and identify predictors of sustained virological response at week 24 (SVR24). Methods: 1078 patients with bridging fibrosis (n = 552) or cirrhosis (n = 526) diagnosed by either liver biopsy or non-invasive markers, with compensated bone marrow (neutrophils >1500/ mm3, Hb >12/13 g/dl) and liver function (Albumin >3.3 g/dl, Platelets >90,000/ml) received TVR PR for 12 weeks, followed by a PR tail according to label. Results: Overall, 614 (57%) achieved SVR24 by intention-to-treat analysis. The SVR24 rate was 68% in 221 treatment naïve patients (62.8% F4), 72% in 356 prior relapsers (64.4% F4), 55% in 139 partial responders (53.2% F4), and 34% in 294 null responders (28.6% F4). The SVR24 rate to response-guided therapy (24 weeks treatment duration if undetectable viremia at weeks 4 and 12) was 84% in 222 naïve/relapser F3 patients. Independent predictors of response were: (A) F3 (odds ratio (OR) = 1.51, 95% CI 1.31- 2.00, p = 0.005), (B) subtype 1b (OR = 1.63, 95% CI 1.18-2.24, p = 0.0029), (C) alpha-fetoprotein

Original languageEnglish
Pages (from-to)976-983
Number of pages8
JournalJournal of Hepatology
Volume61
Issue number5
DOIs
Publication statusPublished - 2014

Fingerprint

Hepatitis C
Fibrosis
Odds Ratio
Intention to Treat Analysis
Ribavirin
Liver
Viremia
alpha-Fetoproteins
Therapeutics
Interferon-alpha
Hepacivirus
Liver Cirrhosis
Albumins
Neutrophils
Blood Platelets
Bone Marrow
Genotype
Biopsy
Safety
telaprevir

Keywords

  • Cirrhosis
  • Hepatitis C
  • Pegylated interferon
  • Telaprevir

ASJC Scopus subject areas

  • Hepatology
  • Medicine(all)

Cite this

Sustained virological response with telaprevir in 1078 patients with advanced hepatitis C : The international telaprevir access program. / Colombo, Massimo; Strasser, Simone; Moreno, Christophe; Ferreira, Paulo Abrao; Urbanek, Petr; Fernández, Inmaculada; Abdurakmonov, Djamal; Streinu-Cercel, Adrian; Verheyen, Anke; Iraqi, Wafae; DeMasi, Ralph; Hill, Andrew; Lonjon-Domanec, Isabelle; Wedemeyer, Heiner.

In: Journal of Hepatology, Vol. 61, No. 5, 2014, p. 976-983.

Research output: Contribution to journalArticle

Colombo, M, Strasser, S, Moreno, C, Ferreira, PA, Urbanek, P, Fernández, I, Abdurakmonov, D, Streinu-Cercel, A, Verheyen, A, Iraqi, W, DeMasi, R, Hill, A, Lonjon-Domanec, I & Wedemeyer, H 2014, 'Sustained virological response with telaprevir in 1078 patients with advanced hepatitis C: The international telaprevir access program', Journal of Hepatology, vol. 61, no. 5, pp. 976-983. https://doi.org/10.1016/j.jhep.2014.06.005
Colombo, Massimo ; Strasser, Simone ; Moreno, Christophe ; Ferreira, Paulo Abrao ; Urbanek, Petr ; Fernández, Inmaculada ; Abdurakmonov, Djamal ; Streinu-Cercel, Adrian ; Verheyen, Anke ; Iraqi, Wafae ; DeMasi, Ralph ; Hill, Andrew ; Lonjon-Domanec, Isabelle ; Wedemeyer, Heiner. / Sustained virological response with telaprevir in 1078 patients with advanced hepatitis C : The international telaprevir access program. In: Journal of Hepatology. 2014 ; Vol. 61, No. 5. pp. 976-983.
@article{9d10179141174dd5a8ba31a8fa55c228,
title = "Sustained virological response with telaprevir in 1078 patients with advanced hepatitis C: The international telaprevir access program",
abstract = "Background & Aims: There is little information regarding the extent to which difficult to cure patients with advanced liver fibrosis, due to hepatitis C virus genotype-1 (HCV-1) can successfully and safely be treated with triple therapy with telaprevir (TVR), pegylated interferon alpha (P) and ribavirin (R). In the TVR early access program HEP3002 we aimed to explore treatment safety and efficacy, and identify predictors of sustained virological response at week 24 (SVR24). Methods: 1078 patients with bridging fibrosis (n = 552) or cirrhosis (n = 526) diagnosed by either liver biopsy or non-invasive markers, with compensated bone marrow (neutrophils >1500/ mm3, Hb >12/13 g/dl) and liver function (Albumin >3.3 g/dl, Platelets >90,000/ml) received TVR PR for 12 weeks, followed by a PR tail according to label. Results: Overall, 614 (57{\%}) achieved SVR24 by intention-to-treat analysis. The SVR24 rate was 68{\%} in 221 treatment na{\"i}ve patients (62.8{\%} F4), 72{\%} in 356 prior relapsers (64.4{\%} F4), 55{\%} in 139 partial responders (53.2{\%} F4), and 34{\%} in 294 null responders (28.6{\%} F4). The SVR24 rate to response-guided therapy (24 weeks treatment duration if undetectable viremia at weeks 4 and 12) was 84{\%} in 222 na{\"i}ve/relapser F3 patients. Independent predictors of response were: (A) F3 (odds ratio (OR) = 1.51, 95{\%} CI 1.31- 2.00, p = 0.005), (B) subtype 1b (OR = 1.63, 95{\%} CI 1.18-2.24, p = 0.0029), (C) alpha-fetoprotein",
keywords = "Cirrhosis, Hepatitis C, Pegylated interferon, Telaprevir",
author = "Massimo Colombo and Simone Strasser and Christophe Moreno and Ferreira, {Paulo Abrao} and Petr Urbanek and Inmaculada Fern{\'a}ndez and Djamal Abdurakmonov and Adrian Streinu-Cercel and Anke Verheyen and Wafae Iraqi and Ralph DeMasi and Andrew Hill and Isabelle Lonjon-Domanec and Heiner Wedemeyer",
year = "2014",
doi = "10.1016/j.jhep.2014.06.005",
language = "English",
volume = "61",
pages = "976--983",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier B.V.",
number = "5",

}

TY - JOUR

T1 - Sustained virological response with telaprevir in 1078 patients with advanced hepatitis C

T2 - The international telaprevir access program

AU - Colombo, Massimo

AU - Strasser, Simone

AU - Moreno, Christophe

AU - Ferreira, Paulo Abrao

AU - Urbanek, Petr

AU - Fernández, Inmaculada

AU - Abdurakmonov, Djamal

AU - Streinu-Cercel, Adrian

AU - Verheyen, Anke

AU - Iraqi, Wafae

AU - DeMasi, Ralph

AU - Hill, Andrew

AU - Lonjon-Domanec, Isabelle

AU - Wedemeyer, Heiner

PY - 2014

Y1 - 2014

N2 - Background & Aims: There is little information regarding the extent to which difficult to cure patients with advanced liver fibrosis, due to hepatitis C virus genotype-1 (HCV-1) can successfully and safely be treated with triple therapy with telaprevir (TVR), pegylated interferon alpha (P) and ribavirin (R). In the TVR early access program HEP3002 we aimed to explore treatment safety and efficacy, and identify predictors of sustained virological response at week 24 (SVR24). Methods: 1078 patients with bridging fibrosis (n = 552) or cirrhosis (n = 526) diagnosed by either liver biopsy or non-invasive markers, with compensated bone marrow (neutrophils >1500/ mm3, Hb >12/13 g/dl) and liver function (Albumin >3.3 g/dl, Platelets >90,000/ml) received TVR PR for 12 weeks, followed by a PR tail according to label. Results: Overall, 614 (57%) achieved SVR24 by intention-to-treat analysis. The SVR24 rate was 68% in 221 treatment naïve patients (62.8% F4), 72% in 356 prior relapsers (64.4% F4), 55% in 139 partial responders (53.2% F4), and 34% in 294 null responders (28.6% F4). The SVR24 rate to response-guided therapy (24 weeks treatment duration if undetectable viremia at weeks 4 and 12) was 84% in 222 naïve/relapser F3 patients. Independent predictors of response were: (A) F3 (odds ratio (OR) = 1.51, 95% CI 1.31- 2.00, p = 0.005), (B) subtype 1b (OR = 1.63, 95% CI 1.18-2.24, p = 0.0029), (C) alpha-fetoprotein

AB - Background & Aims: There is little information regarding the extent to which difficult to cure patients with advanced liver fibrosis, due to hepatitis C virus genotype-1 (HCV-1) can successfully and safely be treated with triple therapy with telaprevir (TVR), pegylated interferon alpha (P) and ribavirin (R). In the TVR early access program HEP3002 we aimed to explore treatment safety and efficacy, and identify predictors of sustained virological response at week 24 (SVR24). Methods: 1078 patients with bridging fibrosis (n = 552) or cirrhosis (n = 526) diagnosed by either liver biopsy or non-invasive markers, with compensated bone marrow (neutrophils >1500/ mm3, Hb >12/13 g/dl) and liver function (Albumin >3.3 g/dl, Platelets >90,000/ml) received TVR PR for 12 weeks, followed by a PR tail according to label. Results: Overall, 614 (57%) achieved SVR24 by intention-to-treat analysis. The SVR24 rate was 68% in 221 treatment naïve patients (62.8% F4), 72% in 356 prior relapsers (64.4% F4), 55% in 139 partial responders (53.2% F4), and 34% in 294 null responders (28.6% F4). The SVR24 rate to response-guided therapy (24 weeks treatment duration if undetectable viremia at weeks 4 and 12) was 84% in 222 naïve/relapser F3 patients. Independent predictors of response were: (A) F3 (odds ratio (OR) = 1.51, 95% CI 1.31- 2.00, p = 0.005), (B) subtype 1b (OR = 1.63, 95% CI 1.18-2.24, p = 0.0029), (C) alpha-fetoprotein

KW - Cirrhosis

KW - Hepatitis C

KW - Pegylated interferon

KW - Telaprevir

UR - http://www.scopus.com/inward/record.url?scp=84932190976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84932190976&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2014.06.005

DO - 10.1016/j.jhep.2014.06.005

M3 - Article

VL - 61

SP - 976

EP - 983

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 5

ER -